MAPK13 Inhibitor Compounds Selective Kinase Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current MAPK inhibitors lack selectivity and effectiveness in targeting specific mitogen-activated protein kinases (MAPKs), particularly MAPK13, and their broader specificity compounds do not consistently achieve desired inhibitory effects.
Innovation Solution
Development of compounds with specific structures, such as those outlined in Formulas I, II, and III, which target individual MAPKs like MAPK13 or multiple MAPKs including combinations like MAPK13 and MAPK14, offering high specificity and inhibitory properties as shown in Table 1 and Table 2.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If current MAPK inhibitors are used, then broader MAPK coverage is achieved, but selectivity for specific MAPKs (particularly MAPK13) deteriorates
Solution Approach 1:
The patent segments the broad MAPK inhibition approach into specific inhibitor classes tailored for individual MAPKs or small groups. The compounds are designed with specific structural features that target particular MAPK isoforms (e.g., MAPK13, MAPK14, or combinations), thereby achieving selective inhibition while maintaining coverage of multiple kinases through a series of specialized inhibitors rather than one broad-spectrum agent.
Solution Approach 2:
The invention applies local quality by designing compounds with specific molecular characteristics that confer selectivity for particular MAPKs. The structural modifications at specific positions of the inhibitor molecules create localized interactions that preferentially bind to certain MAPK isoforms, enabling differentiated inhibition patterns across the MAPK family.
2Adaptability or versatility
If current MAPK inhibitors are used, then broader MAPK coverage is achieved, but inhibitory effectiveness deteriorates
Solution Approach 1:
The patent divides the inhibition strategy into specialized inhibitor classes, each optimized for specific MAPK targets. This segmentation allows each compound to achieve high inhibitory effectiveness against its intended targets while the collection of compounds provides broad MAPK coverage, resolving the contradiction between effectiveness and versatility.
Solution Approach 2:
The invention employs parameter changes by systematically modifying molecular parameters (structural features, functional groups, stereochemistry) to optimize inhibitory effectiveness for specific MAPKs. These parameter adjustments enhance binding affinity and selectivity, ensuring reliable inhibition of target kinases while maintaining the ability to cover multiple MAPKs through different compound variants.
3Manufacturing precision
If compounds with high specificity for individual MAPKs are developed, then selectivity is improved, but the complexity of targeting multiple MAPKs increases
Solution Approach 1:
The patent applies universality by designing inhibitor classes that can target multiple MAPK isoforms within a unified structural framework. The core molecular scaffold serves multiple functions by binding to different MAPKs, reducing the need for entirely separate compounds for each target and simplifying the overall targeting strategy while maintaining high selectivity.
Solution Approach 2:
The invention incorporates dynamics by creating a flexible classification system where inhibitor specificity can be tuned and adjusted. The structural parameters of the compounds can be dynamically modified to shift selectivity profiles, allowing adaptation to different therapeutic needs and simplifying the management of multiple targets through a adaptable molecular platform.
Data Source
AI summary
Compounds that inhibit mitogen-activated protein kinases (MAPKs) are disclosed. Some inhibitor compounds specifically target a single MAPK such as MAPK13, while others target multiple MAPKs such as MAPK13 and MAPK12. The compounds can be used therapeutically for a variety of diseases, including cancer and respiratory diseases. Methods of synthesis of the compounds are also disclosed.